Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protoporphyrin IX is an organic compound classified as a porphyrin, specifically a cyclic tetrapyrrole that serves as a critical intermediate in the biosynthesis of heme and chlorophyll. It is the iron-free form of hemin, featuring a highly conjugated ring system that allows it to function as a potent **photosensitizing agent**. In clinical and research contexts, protoporphyrin IX is used primarily as a photosensitizer for **photodynamic therapy (PDT)**—where, when activated by light, it produces reactive oxygen species that can selectively destroy cancer cells. Protoporphyrin IX is also a metabolic precursor in heme biosynthesis pathways and is commonly assessed as a biomarker for various metabolic disorders. It has additional biological activities, including roles in cellular respiration, liver function, and as an inhibitor of p53/MDM2 and p53/MDM4 protein interactions, which contributes to induction of apoptosis in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on protoporphyrin IX.